313 related articles for article (PubMed ID: 27655283)
1. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study.
Ríos Peces S; Díaz Navarro C; Márquez López C; Caba O; Jiménez-Luna C; Melguizo C; Prados JC; Genilloud O; Vicente Pérez F; Pérez Del Palacio J
SLAS Discov; 2017 Apr; 22(4):348-359. PubMed ID: 27655283
[TBL] [Abstract][Full Text] [Related]
2. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
[TBL] [Abstract][Full Text] [Related]
3. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
[TBL] [Abstract][Full Text] [Related]
4. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
[TBL] [Abstract][Full Text] [Related]
5. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.
Pang Y; Holmes MV; Chen Z; Kartsonaki C
J Gastroenterol Hepatol; 2019 Feb; 34(2):330-345. PubMed ID: 30550622
[TBL] [Abstract][Full Text] [Related]
6. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer.
Urayama S; Zou W; Brooks K; Tolstikov V
Rapid Commun Mass Spectrom; 2010 Mar; 24(5):613-20. PubMed ID: 20143319
[TBL] [Abstract][Full Text] [Related]
8. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
Sahni S; Pandya AR; Hadden WJ; Nahm CB; Maloney S; Cook V; Toft JA; Wilkinson-White L; Gill AJ; Samra JS; Dona A; Mittal A
Int J Cancer; 2021 Mar; 148(6):1508-1518. PubMed ID: 33128797
[TBL] [Abstract][Full Text] [Related]
9. LC-MS/MS and SWATH based serum metabolomics enables biomarker discovery in pancreatic cancer.
Xiong Y; Shi C; Zhong F; Liu X; Yang P
Clin Chim Acta; 2020 Jul; 506():214-221. PubMed ID: 32243985
[TBL] [Abstract][Full Text] [Related]
10. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer.
Byeon S; McKay MJ; Molloy MP; Gill AJ; Samra JS; Mittal A; Sahni S
Int J Cancer; 2024 Jul; 155(2):365-371. PubMed ID: 38519999
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the technical variations and the suitability of a hydrophilic interaction liquid chromatography-high resolution mass spectrometry (ZIC-pHILIC-Exactive orbitrap) for clinical urinary metabolomics study.
Zhang T; Watson DG
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1022():199-205. PubMed ID: 27107246
[TBL] [Abstract][Full Text] [Related]
13. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.
Mellby LD; Nyberg AP; Johansen JS; Wingren C; Nordestgaard BG; Bojesen SE; Mitchell BL; Sheppard BC; Sears RC; Borrebaeck CAK
J Clin Oncol; 2018 Oct; 36(28):2887-2894. PubMed ID: 30106639
[TBL] [Abstract][Full Text] [Related]
14. Serum N-Glycome analysis reveals pancreatic cancer disease signatures.
Vreeker GCM; Hanna-Sawires RG; Mohammed Y; Bladergroen MR; Nicolardi S; Dotz V; Nouta J; Bonsing BA; Mesker WE; van der Burgt YEM; Wuhrer M; Tollenaar RAEM
Cancer Med; 2020 Nov; 9(22):8519-8529. PubMed ID: 32898301
[TBL] [Abstract][Full Text] [Related]
15. Metabonomic alterations from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma facilitate the identification of biomarkers in serum for early diagnosis of pancreatic cancer.
Lin X; Zhan B; Wen S; Li Z; Huang H; Feng J
Mol Biosyst; 2016 Aug; 12(9):2883-92. PubMed ID: 27400832
[TBL] [Abstract][Full Text] [Related]
16. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma.
Byrling J; Hilmersson KS; Ansari D; Andersson R; Andersson B
Clin Transl Oncol; 2022 Feb; 24(2):297-304. PubMed ID: 34319497
[TBL] [Abstract][Full Text] [Related]
17. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
19. Liquid chromatography-mass spectrometry untargeted metabolomics reveals increased levels of tryptophan indole metabolites in urine of metabolic syndrome patients.
Esperanza MG; Wrobel K; Ojeda AG; Garay-Sevilla ME; Escobosa ARC; Barrientos EY; Wrobel K
Eur J Mass Spectrom (Chichester); 2020 Dec; 26(6):379-387. PubMed ID: 33295818
[TBL] [Abstract][Full Text] [Related]
20. A novel serum metabolomics-based diagnostic approach to pancreatic cancer.
Kobayashi T; Nishiumi S; Ikeda A; Yoshie T; Sakai A; Matsubara A; Izumi Y; Tsumura H; Tsuda M; Nishisaki H; Hayashi N; Kawano S; Fujiwara Y; Minami H; Takenawa T; Azuma T; Yoshida M
Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):571-9. PubMed ID: 23542803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]